Professor Lietzan researches, writes, and teaches primarily in the areas of food and drug regulation, intellectual property, and administrative law. Some of her recent scholarship has focused on the nature and purpose of the new drug approval system, federal regulation of fecal microbiota transplantation, federal regulation of products derived from cannabis, the political economy of the Hatch-Waxman (generic drug) statute, and incentives to study already approved drugs for new uses. She is an award-winning teacher, and she has been an elected member of the American Law Institute since 2006.
Professor Lietzan brings to her scholarship and teaching eighteen years of private practice experience, eight of them as a partner in the food and drug group at Covington & Burling in Washington, DC. In practice, she handled a wide range of complex legal problems and broader legislative and regulatory policy questions affecting FDA-regulated companies. This work included lifecycle management and strategy issues, regulatory strategy and advocacy, white collar defense, congressional investigations, briefing in products liability cases, and international regulatory policy work. She was involved in every major amendment to the Federal Food, Drug, and Cosmetic Act (FDCA) between 1997 and 2014 and was deeply immersed for more than a decade in the development of the Biologics Price Competition and Innovation Act of 2010. She has been consistently identified by her peers in private practice as a “Best Lawyer in America” in the categories of FDA law (since 2013) and Biotechnology Law (since 2007).
Professor Lietzan has held one leadership position or another at the Food and Drug Law Institute (FDLI) since 2004, including a stint on its Board of Directors from 2008 to 2012. She also held leadership positions in the American Bar Association’s Section of Science and Technology Law for fourteen years.
Professor Lietzan received a bachelor’s degree from the University of North Carolina, where she graduated with honors in history. She holds a master’s degree in history from UCLA and a law degree with high honors from Duke Law School.
*****
A person listed as a contributor has spoken or otherwise participated in Federalist Society events, publications, or multimedia presentations. A person's appearance on this list does not imply any other endorsement or relationship between the person and the Federalist Society. In most cases, the biographical information on a person's "contributor" page is provided directly by the person, and the Federalist Society does not edit or otherwise endorse that information. The Federalist Society takes no position on particular legal or public policy issues. All expressions of opinion by a contributor are those of the contributor.
Regulation or “Don’t Let a Good Crisis Go to Waste”
COVID-19 & the Law Conference
Webinar & Live StreamPharma Patents and FDA Regulation
Akron Student Chapter
University of Akron School of Law150 University Ave
Akron, OH 44325
Regulation or “Don’t Let a Good Crisis Go to Waste”
COVID-19 & the Law Conference
The fifth panel of the Federalist Society's COVID-19 & the Law Conference discussed "Regulation or...
Regulation or “Don’t Let a Good Crisis Go to Waste”
COVID-19 & the Law Conference
The fifth panel of the Federalist Society's COVID-19 & the Law Conference discussed "Regulation or...
Sandoz, Inc. v. Amgen, Inc. Post-Decision SCOTUScast
SCOTUScast 8-11-17 featuring Erika Lietzan
On June 12, 2017, the Supreme Court decided Sandoz, Inc. v. Amgen, Inc. consolidated with...
Courthouse Steps: Sandoz Inc. v. Amgen Inc. - Podcast
Intellectual Property Practice Group Podcast
In a decision likely to shape not only future biosimilar litigation but the biosimilar industry...
A Second Look at the CREATES Act: What’s Not Being Said
Federalist Society Review, Volume 17, Issue 3
Note from the Editor: This article critically discusses the CREATES Act, which is currently pending...